Fri, Sep 19, 2014, 11:55 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Neurocrine Biosciences Inc. Message Board

  • frogsleapmerlot frogsleapmerlot Aug 19, 2014 7:28 AM Flag

    Hit $17 yesterdays HOD = $20+ PPS coming soon

    The stock does want to go to $20+ PPS Before E P3 Results.

    Positive trial results we head towards $30 as Abbvie will buy out NBIX north of $50

    No reason for NBIX to be a stand alone biotech given its limited pipeline after E and VMAT2

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • frogs,

      "limited pipeline after E and VMAT 2"? Have you forgotten about the two novel compounds for novel indications that are working their way through the "gauntlet"? ;-))))

      I like your buyout target of $50, but I think Kevy is bent on keeping VMAT2 in the US as his rice bowl.

      Ochs

      • 1 Reply to ochsnerbier
      • preclinical pipeline means very little in terms of valuation. If Abbvie comes shopping their will be very little kevy and the boys will be able to do. Abbvie management team are master at takeovers.

        i have been around NBIX as an investment since around 1997/98 ,,,,, long, on the side lines, long, on the side lines, long. My current position I bought in 2010 Have sold 60% of it since than.

        I know management and given their track record I'll be very happy with $50 in the bank

    • Elagolix is an exciting compound that seems to be superior to the current therapy, particularly in an oral tablet. The pharmacological mechanism of this pill is very clear and predictable. There are some confusion to me when Abbvie will report P3 results on Elagolix. And will Abbvie report the full results or just the top line data? If you could share the information, I would greatly appreciate. Go NBIX

 
NBIX
16.02-0.37(-2.26%)Sep 19 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.